Reaction
Pancreatic Mass reporting signals
As of the last recalculation, Pancreatic Mass appears in 1,046 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 34.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pancrelipase | 63 | 34.5 | 34.6 |
| Sitagliptin | 73 | 21.6 | 21.6 |
| Erythromycin | 19 | 20.5 | 20.5 |
| Sitagliptin And Metformin Hydrochloride | 19 | 17.8 | 17.9 |
| Liraglutide | 34 | 14.1 | 14.1 |
| Insulin Glulisine | 7 | 13.8 | 13.8 |
| Exenatide | 31 | 12.1 | 12.1 |
| Gemcitabine Hydrochloride | 29 | 11.2 | 11.2 |
| Irinotecan Hydrochloride | 7 | 10.9 | 10.9 |
| Gemcitabine | 19 | 9.8 | 9.8 |
| Pazopanib Hydrochloride | 10 | 7.4 | 7.4 |
| Ledipasvir And Sofosbuvir | 5 | 5.2 | 5.2 |
| Cabozantinib | 12 | 5.0 | 5.0 |
| Dulaglutide | 17 | 3.9 | 3.9 |